Chief Accounting Officer
Biocryst Pharmaceuticals Inc (BCRX)Equibles does not estimate personal net worth.
Get an email with a short summary when Biocryst Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get BCRX alertsBabar Ghias is recorded as Chief Accounting Officer at Biocryst Pharmaceuticals Inc (BCRX) since July 7, 2025 and CFO at Biocryst Pharmaceuticals Inc (BCRX). The newest filing on record that lists Babar Ghias as CFO at Biocryst Pharmaceuticals Inc (BCRX) is dated April 23, 2026. Biocryst Pharmaceuticals Inc reported in an 8-K filed July 7, 2025 that Babar Ghias was appointed Principal Accounting Officer, effective July 7, 2025. Biocryst Pharmaceuticals Inc reported in an 8-K filed July 7, 2025 that Babar Ghias was appointed Chief Financial Officer, effective July 7, 2025. The proxy statement of Biocryst Pharmaceuticals Inc reports total compensation of $6,748,152 for Babar Ghias in fiscal 2025, including a base salary of $271,515. Babar Ghias has spoken on 6 earnings calls across 1 company, most recently for Biocryst Pharmaceuticals Inc on November 4, 2026. Biocryst Pharmaceuticals Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Biocryst Pharmaceuticals Inc includes Charles Gayer (CEO and Board Member), Charlie Gayer (CEO and Board Member), Vincent J. Milano (Chairman and Board Member) and 7 others.
“Mr. Ghias will also serve as the Company’s Principal Accounting Officer and Head of Corporate Development, effective as of July 7, 2025.”
“On July 7, 2025, BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), announced the appointment of Babar Ghias, age 46, as Chief Financial Officer of the Company, effective as of July 7, 2025, and as approved by the Company’s Board of Directors (the “Board”) on June 11, 2025.”
“We are pleased to share the results of a very strong third quarter, which included not only the important accomplishments just described, but also continued financial excellence.”
“Our second fiscal quarter reflected continued momentum across the business, steady growth in Oladeo, substantial progress across our clinical pipeline, as you heard, and very importantly, a key step forward in resolving the manufacturing issue to get our pediatric launch in the way.”
“In my remarks today, I will be referring to non-GAAP figures which are adjusted for revenues and expenses related to our European holiday business, stock-based com, and expenses related to the acquisition of Astria.”
“Last year was a defining year for our company. We delivered strong top-line growth, record profitability, and reinforced our strong balance sheet position. Those results weren't just numbers.”
“My first full quarter as CFO of BioCryst was extremely eventful and was marked by several significant achievements, which I believe position us well for future growth and profitability.”
2025-07-07–present
2025-07-07–present
Start not stated–present
Last confirmed April 23, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CFO, Chief Accounting Officer
2025-07-07–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Biocryst Pharmaceuticals Inc (BCRX) | Chief Financial Officer | $271,515 | $6,748,152 |
